Questions
What did Moderna promise about its Covid vaccine price?
Moderna said anyone in the United States who wants a booster can get it with no out-of-pocket cost, mainly through a patient assistance program for uninsured and underinsured people. The hosts note it did not explain how people on commercial insurance would pay nothing, and that list prices may still rise.
Why does Novartis's CEO say the Inflation Reduction Act hurts innovation?
Narasimhan says it lets Medicare set prices on small-molecule drugs after nine years, and that this covers about 60% of the industry's drugs. He argues that is too little time to recover the cost of expanding a drug to new uses, especially in cancer, rare disease and heart disease.
What does it mean that Novartis is becoming a 'pure play' innovative medicines company?
It means Novartis has shed its other businesses, such as consumer health, eye care devices and Sandoz generics, and now focuses only on developing new prescription medicines. Narasimhan says it did about $100 billion of transactions over five years to get there.
Why is Novartis limiting biotech acquisitions to about $5 billion?
Narasimhan says the best opportunity is in mid-stage companies below that size, where Novartis can add its expertise and scale. He also says high-quality science is hard to find, and cheaply priced assets are not worth buying if the development work was not done rigorously.
Is the Narcan advisory committee decision final?
No. The FDA advisory committee voted 19 to 0 in favor of moving Emergent BioSolutions' Narcan nasal spray over the counter, and Meg Terrell says the FDA is likely to approve it. The price remains an open question.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Moderna CEO Stéphane Bancel agreed to testify at a Senate HELP Committee hearing, led by Bernie Sanders and scheduled for March 22, about the planned Covid vaccine price increase.
“touting that Moderna CEO Stefan Boncel had agreed to appear and testify in a hearing sort of hilariously titled, taxpayers paid billions for it.”
0:03:09 · Meg Terrell · Senate hearing · 2023
Pfizer CEO Albert Bourla has said that provisions in the Inflation Reduction Act would remove copays for insured people, including for Covid vaccines.
“this is something that Pfizer CEO Albert Bourla has been out there on as well, actually saying that there are provisions in the Inflation Reduction Act that would take away any co-pays that insured people have”
0:04:14 · Meg Terrell · Vaccine copays · 2023
Stelios Papadopoulos, Biogen's longtime chairman, is stepping back from the board because of the company's mandatory age retirement policy.
“Stelios Papadopoulos, the longtime chairman, is resigning from the war, stepping back from the board. And that's due to Biogen's mandatory age retirement policy.”
0:07:56 · Adam Feuerstein · Biogen board · 2023
Narcan is the brand name of the nasal spray version of naloxone, an opioid overdose antidote that has existed since the 1970s.
“Narcan is the brand name for the nasal spray version of naloxone, the opioid overdose antidote, this incredible drug that's been around since the 70s”
0:08:56 · Meg Terrell · Narcan · 1970s
Emergent BioSolutions, which applied to sell Narcan over the counter, manufactured the J&J and AstraZeneca Covid vaccines during the pandemic and mixed up some of the ingredients.
“This is the company that famously during the pandemic was manufacturing the J &J vaccine and the AstraZeneca vaccine and mixed up some of the ingredients.”
0:08:56 · Meg Terrell · Emergent BioSolutions · 2021
An FDA advisory committee voted 19 to 0 in favor of making Emergent BioSolutions' Narcan nasal spray available over the counter.
“And the committee ended up voting 19 to 0 in favor of turning this over the counter.”
0:09:32 · Meg Terrell · Narcan vote · 2023
John Reed, who had spent about five years running research and development at Sanofi, left the company and was hired by Johnson & Johnson as its chief scientific officer.
“John Reed, who had spent about five years running the research and development operation at Sanofi, would be leaving the company.”
0:10:40 · Damian Garde · Pharma executives · 2023
John Reed replaces Mathai Mammen at Johnson & Johnson; Mammen was briefly a candidate for the Biogen CEO position before leaving J&J's top research role.
“he's replacing Matai Mamon, who we've spoken about, was briefly a candidate for the Biogen CEO position”
0:10:40 · Damian Garde · Pharma executives · 2023
Politico reported that Vivek Ramaswamy, a biotech entrepreneur and former hedge fund manager, was testing the waters for a presidential run.
“there was a story in Politico this week that basically said that Vivek Ramaswamy, as you said, Meg, he's the biotech entrepreneur, former hedge fund manager.”
0:12:09 · Adam Feuerstein · Presidential run · 2023
Damian Garde says Vivek Ramaswamy's media prominence rests on his criticism of large asset managers such as BlackRock for pursuing ESG and diversity agendas with clients' money.
“Vivek's star turn on Tucker Carlson and elsewhere is based on this notion that wealth managers, the black rocks of the world, by focusing on what is described as ESG”
0:13:08 · Damian Garde · ESG criticism · 2023
Activist investor Bill Ackman publicly supported Vivek Ramaswamy on Twitter during the week of this episode.
“I think that is a point that was also made by activist investor Bill Ackman, who threw his support behind Vivek on Twitter this week.”
0:14:52 · Meg Terrell · Political support · 2023
Novartis CEO Vas Narasimhan became chair of the board of PhRMA, the trade group representing the drug industry, in early 2023.
“last week there was a change at the top of pharma or the pharmaceutical research and manufacturers of america which is of course the trade group representing the drug industry”
0:16:41 · Damian Garde · PhRMA leadership · 2023
Adam Feuerstein said PhRMA spends about $30 million a year on lobbying.
“taken for pharma, a group that spends about $30 million a year in lobbying. What are the issues that you are most focused on there?”
0:17:15 · Adam Feuerstein · Lobbying · 2023
Vas Narasimhan argues that the Inflation Reduction Act's nine years before price controls for small-molecule drugs is too short to allow indication expansions, rare disease work and oncology and cardiovascular development.
“we believe that the nine years of protection before price controls take hold in the small molecule space is simply too short to really allow us to do the indication expansions”
0:17:23 · Vas Narasimhan · Inflation Reduction Act · 2022
Narasimhan said that in many drug classes, rebates can be as much as 70% of a drug's list price.
“as you know, in many drug classes, that rebate can be as much as 70 % of the list price of the drug.”
0:18:22 · Vas Narasimhan · PBM rebates · 2023
Narasimhan said small-molecule drugs, which face price setting after nine years under the Inflation Reduction Act, make up about 60% of the drugs the industry generates.
“that will have a big impact on what is really about 60% of the drugs this industry generates and many of those drugs targeting the elderly population.”
0:20:04 · Vas Narasimhan · Small-molecule drugs · 2023
Novartis traces its roots to dye-making and chemicals, and was created in its current form in 1996.
“it's a 250-year-old company. It started in the dye-making industry, went to chemicals, and then slowly evolved into a healthcare conglomerate when Novartis in its current form was created in 1996.”
0:23:51 · Vas Narasimhan · Novartis history · 1996
Over about five years, Novartis did roughly $100 billion of transactions to exit consumer health and eye care devices, plan the Sandoz spin-off and sell its Roche stake.
“So over the last five years, we've done about $100 billion of transactions to exit consumer health, eye care devices, our planned spin of Sandoz”
0:24:28 · Vas Narasimhan · Novartis divestitures · 2018-2023
Novartis sees its best opportunity for biotech acquisitions in mid-stage development companies valued below about $5 billion.
“Right now, where we see the biggest opportunity to find value is in this kind of sub $5 billion, I would say, mid-stage development space.”
0:26:51 · Vas Narasimhan · Biotech M&A · 2023
Novartis's gene therapy Zolgensma is a blockbuster medicine reimbursed in 38 countries, according to Vas Narasimhan.
“It's a blockbuster medicine. We're reimbursed in 38 countries.”
0:31:27 · Vas Narasimhan · Zolgensma · 2023
Narasimhan said CAR-T cell therapy has struggled to move from B cell cancers into solid tumors because solid tumors are heterogeneous and reliable targets are hard to find.
“There was a huge amount of effort to move from B cell tumors into solid tumors. Solid tumors are so heterogeneous, it's been hard to find, I think, reliable targets”
0:35:33 · Vas Narasimhan · CAR-T therapy · 2023
Narasimhan expects siRNA therapies that patients need only every six months or year, especially if directed beyond the liver, to transform healthcare over time.
“long-acting therapies that patients only need every six months or one year are going to transform healthcare over time.”
0:36:43 · Vas Narasimhan · siRNA therapies